Back to Search Start Over

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

Authors :
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service de gastro-entérologie
Flourié, B
Hagège, H
Tucat, G
Maetz, D
Hébuterne, X
Kuyvenhoven, J P
Tan, T G
Pierik, M J
Masclee, A A M
Dewit, Olivier
Probert, C S
Aoucheta, D
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service de gastro-entérologie
Flourié, B
Hagège, H
Tucat, G
Maetz, D
Hébuterne, X
Kuyvenhoven, J P
Tan, T G
Pierik, M J
Masclee, A A M
Dewit, Olivier
Probert, C S
Aoucheta, D
Source :
Alimentary Pharmacology and Therapeutics, Vol. 37, no.8, p. 767-775 (2013)
Publication Year :
2013

Abstract

When combined with mesalazine enema, prolonged-release mesalazine once-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis (Clinicaltrials.gov: NCT00737789).

Details

Database :
OAIster
Journal :
Alimentary Pharmacology and Therapeutics, Vol. 37, no.8, p. 767-775 (2013)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1130496297
Document Type :
Electronic Resource